Paloma Partners Management Co Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Paloma Partners Management Co raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 11,709 shares of the medical research company’s stock after acquiring an additional 538 shares during the period. Paloma Partners Management Co’s holdings in IQVIA were worth $2,775,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of IQV. Versant Capital Management Inc grew its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the second quarter valued at approximately $27,000. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter worth approximately $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the third quarter worth $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA during the 2nd quarter valued at $29,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Friday, November 1st. Finally, The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Price Performance

IQV stock opened at $200.84 on Monday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market capitalization of $36.45 billion, a price-to-earnings ratio of 26.36, a PEG ratio of 2.07 and a beta of 1.51. The firm has a 50 day moving average price of $218.67 and a 200-day moving average price of $226.11. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.